<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690075</url>
  </required_header>
  <id_info>
    <org_study_id>DFiber-CD-2020-2021</org_study_id>
    <nct_id>NCT04690075</nct_id>
  </id_info>
  <brief_title>Effect of Dietary Fiber on Metabolism, Inflammation and Nutritional Status in Patients With Chronic Diseases</brief_title>
  <official_title>Dietary Fiber in Nutritional Therapy for Chronic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of chronic disease is increasing rapidly in China. Medical nutritional therapy&#xD;
      (MNT) is essential for the prevention and control of chronic diseases. For example, dietary&#xD;
      fiber plays an important role in chronic disease management. Evidence suggests that&#xD;
      increasing fiber intake can decrease the risk of chronic diseases, such as&#xD;
      overweight/obesity, hyperlipidemia, hyperglycemia, GI diseases, etc. However, according to&#xD;
      the nation-wide survey, the dietary fiber intake of Chinese people shows a downward trend in&#xD;
      recent years, and the relationship between dietary fiber and metabolism of chronic patients&#xD;
      is still controversial. So, this study aims to explore the effects of dietary fiber on&#xD;
      metabolism, inflammatory factors and nutritional status among patients with chronic diseases,&#xD;
      so as to provide reference for proper nutrition intervention towards chronic disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators plan to recruit potential participants in hospital clinics using posters. An&#xD;
      anticipated total of 120 patients with chronic diseases (including overweight, obesity,&#xD;
      hyperlipemia, hyperglycemia, etc) will be randomized to receive oat beta-glucans (study&#xD;
      group) or routine nutrition management (control group) respectively. The outcome parameters,&#xD;
      including weight, blood glucose level, blood fat level, etc, will be measured and compared&#xD;
      over a 12-week intervention period. Intention-to-treat analysis (ITT) and per-protocol&#xD;
      analysis (PP) will be conducted in statistical analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of total cholesterol (TC) level</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Total cholesterol (TC) level obtained from laboratory test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of low density lipoprotein (LDL) cholesterol level</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Low density lipoprotein (LDL) cholesterol level obtained from laboratory test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of interleukin-6 (IL-6) level</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Interleukin-6 (IL-6) level obtained from laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of tumor necrosis factor-alpha level</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Change of tumor necrosis factor-alpha level obtained from laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of triglyceride (TG) level</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Change of triglyceride (TG) level obtained from laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of high density lipoprotein (HDL) cholesterol level</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Change of high density lipoprotein (HDL) cholesterol level obtained from laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of fasting blood glucose (FBG) level</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Change of fasting blood glucose (FBG) level obtained from laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of 2 hours postprandial blood glucose level</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Change of 2 hours postprandial blood glucose level obtained from laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of hemoglobin level</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Change of hemoglobin level obtained from laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of total body fat level</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Change of total body fat level obtained from bioelectrical impedance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Percent of body fat (PBF) level</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Change of percent of body fat (PBF) level obtained from bioelectrical impedance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of visceral fat area (VFA) level</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Change of visceral fat area (VFA) level obtained from bioelectrical impedance analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Disease</condition>
  <condition>Dietary Fiber</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To receive routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To receive routine nutrition management for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutrition Management and Dietary Fiber</intervention_name>
    <description>Routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutrition Management</intervention_name>
    <description>Routine nutrition management for 12 weeks.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-70y&#xD;
&#xD;
          -  Be diagnosed with obesity, hyperlipemia or hyperglycemia&#xD;
&#xD;
          -  Fully understood and voluntarily signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary hyperlipidemia or hyperglycemia&#xD;
&#xD;
          -  Multiple organ failure&#xD;
&#xD;
          -  Allergic or intolerant to dietary fiber(dietary supplement)&#xD;
&#xD;
          -  Have gastrointestinal diseases&#xD;
&#xD;
          -  Have a history of abdominal diseases&#xD;
&#xD;
          -  Experienced intra-abdominal surgery&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kang Yu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kang Yu, M.D.</last_name>
    <phone>+86 01-69155550</phone>
    <email>yuk1997@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaodong Nie, Dr</last_name>
    <phone>+8615832108663</phone>
    <email>drdoranie@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kang Yu, M.D.</last_name>
      <phone>+86 01-69155550</phone>
      <email>yuk1997@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Fang Wang, M.D.</last_name>
      <phone>+8615201646084</phone>
      <email>yours.fang@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q, Li Y, Zhao Z, Qin X, Jin D, Zhou M, Tang X, Hu Y, Wang L. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA. 2017 Jun 27;317(24):2515-2523. doi: 10.1001/jama.2017.7596.</citation>
    <PMID>28655017</PMID>
  </reference>
  <reference>
    <citation>Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267-78. Epub 2005 Sep 27. Erratum in: Lancet. 2005 Oct 15-21;366(9494):1358. Lancet. 2008 Jun 21;371(9630):2084.</citation>
    <PMID>16214597</PMID>
  </reference>
  <reference>
    <citation>Ren J, Grundy SM, Liu J, Wang W, Wang M, Sun J, Liu J, Li Y, Wu Z, Zhao D. Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: the results of a 15-Year Chinese Multi-Provincial Cohort Study (CMCS). Atherosclerosis. 2010 Jul;211(1):327-32. doi: 10.1016/j.atherosclerosis.2010.02.020. Epub 2010 Feb 21.</citation>
    <PMID>20223457</PMID>
  </reference>
  <reference>
    <citation>Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-154. doi: 10.2337/dc16-2042. Review.</citation>
    <PMID>27999003</PMID>
  </reference>
  <reference>
    <citation>Nutrition recommendations and principles for people with diabetes mellitus. American Diabetes Association. J Fla Med Assoc. 1998 Aug;85(2):25-9.</citation>
    <PMID>9782716</PMID>
  </reference>
  <reference>
    <citation>Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89. doi: 10.1056/NEJMoa0806470. Epub 2008 Sep 10.</citation>
    <PMID>18784090</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Yu Kang, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>dietary fiber</keyword>
  <keyword>chronic disease</keyword>
  <keyword>metabolism</keyword>
  <keyword>inflammation</keyword>
  <keyword>nutritional status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

